Stock OLMA OLEMA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Olema Pharmaceuticals, Inc.

Equities

OLMA

US68062P1066

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-03 pm EDT 		5-day change 1st Jan Change
11.76 USD +21.49% Intraday chart for Olema Pharmaceuticals, Inc. +29.80% -16.18%
May. 15 Olema Pharmaceuticals, Inc. Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 Esmo Breast Cancer Congress CI
May. 08 Olema Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Olema Oncology to Participate in Upcoming Investor Conferences in June
GL
Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress
GL
Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
GL
Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress
GL
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
Olema Oncology to Participate in Upcoming Investor Conferences in May
GL
Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
GL
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
GL
Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors
GL
Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors
AQ
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Olema Oncology to Participate in Upcoming Investor Conferences
GL
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate
GL
Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference
GL
Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies
GL
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. OLMA Stock
  4. News Olema Pharmaceuticals, Inc.
  5. Press Releases